Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465101 | 0.86 | AVPR2 (0.44) | AVPR2AVPR1AOPRM1 | |
| SCHEMBL7467171 | 0.86 | AVPR2 (0.44) | AVPR2AVPR1AOPRM1 | |
| SCHEMBL7476504 | 0.86 | AVPR2 (0.44) | AVPR2AVPR1AOPRM1 | |
| SCHEMBL8198317 | 0.84 | AVPR2 (0.38) | AVPR2AVPR1AOPRM1 | |
| SCHEMBL7804157 | 0.82 | ADRB2 (0.39) | KMT2AALDH1A1AVPR2AVPR1AOPRM1 | |
| SCHEMBL23347538 | 0.81 | KMT2A (0.45) | KMT2ATSHRALDH1A1GAAOPRM1 | |
| SCHEMBL2904416 | 0.76 | ADRB1 (0.50) | OPRM1RAB9A | |
| SCHEMBL7465481 | 0.76 | ADRB1 (0.50) | OPRM1RAB9A | |
| SCHEMBL7470205 | 0.76 | ADRB1 (0.50) | OPRM1RAB9A | |
| SCHEMBL14477687 | 0.72 | KMT2A (0.44) | KMT2ATSHRALDH1A1GAAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034365-A1 | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | CHOI YONG MOON (US) | 2001-10-25 | — | — | US | disclosed |
| US-6127412-A | TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANTICONVULSANTS, ANTIEPILEPTIC AND NEUROPROTECTIVE AGENTS AND CENTRALLY ACTING MUSCLE RELAXANTS | SK CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6103759-A | COMPRISING PURE ENANTIOMERIC FORMS, AS WELL AS ENANTIOMERIC MIXTURES, OF (2-(2-CHLOROPHENYL)-2-HYDROXYETHYL)OXYCARBOXAMIDE; USEFUL FOR TRATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SK CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| US-5854283-A | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | YUKONG LIMITED (KR) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034365-A1 | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | DDT, GRIK2, GABRD | KMT2A 471/4885TSHR 2528/4885ALDH1A1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.